Refused · 01
Insurers want to price risk off your record. We will build no access path for underwriting.
Medicine has always overheard fragments of the body's murmur. Homonin is built to hear the whole sentence, early. An ear that fine can be turned toward you as easily as toward your good, so this page is the discipline we impose on our own hearing.
| Fig. | Form | Age | Stage |
|---|---|---|---|
| zygote | day 1 | – | |
| morula | day 3–4 | – | |
| blastocyst | day 5 | – | |
| embryo | day ~20 | CS 9 | |
| embryo | day ~30 | CS 13 | |
| embryo | day ~40 | CS 16 | |
| embryo | day ~48 | CS 19 | |
| embryo | day ~56 | CS 23 | |
| fetus | 10 weeks | – | |
| fetus | 16 weeks | – | |
| fetus | 24 weeks | – | |
| fetus | 36 weeks | – |
For two centuries the body was made legible to the physician, part by lettered part, and to almost no one else. Homonin turns the gaze around. The most detailed picture of your biology should be one you can hold, read and question yourself.
Your record is meant to be read and mapped on your device. Nothing leaves without your action.
A button, not a form buried in settings. Immediate and complete.
Never sold, licensed or shared with third parties for any commercial purpose.
We don't model your behavior to sell it. No advertising product touches health data.
Every setting that shares more can be turned back. Consent is not a one-way ratchet.
Nothing unvalidated is surfaced. Every recommendation links back to its evidence.
A model that influences care must explain itself, or it doesn't ship.
AI surfaces. A clinician or patient decides, and can always override.
A right answer nobody can defend to a patient is not good enough.
The old clinic was built like a panopticon: one tower that sees every cell, and no cell that sees back. Scroll, and turn it around.
Insurers want to price risk off your record. We will build no access path for underwriting.
Employers want fitness-for-work signals. There will be no employer account, so no query to run.
Data brokers want behavioral inference for targeting. We don't build the graph they'd buy.
Researchers at scale want broad secondary use. It requires explicit, revocable, per-study consent, never a default.
That is the whole promise of the biodigital twin, and the reason every rule above exists. If Homonin ever falls short of this page, tell us. We fix it or explain why not.